Genolution Inc. (225220) - Total Assets
Based on the latest financial reports, Genolution Inc. (225220) holds total assets worth ₩99.84 Billion KRW (≈ $67.66 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Genolution Inc. for net asset value and shareholders' equity analysis.
Genolution Inc. - Total Assets Trend (2016–2024)
This chart illustrates how Genolution Inc.'s total assets have evolved over time, based on quarterly financial data.
Genolution Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Genolution Inc.'s total assets of ₩99.84 Billion consist of 35.0% current assets and 65.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩32.17 Billion | 0.0% |
| Accounts Receivable | ₩1.02 Billion | 1.0% |
| Inventory | ₩2.05 Billion | 1.9% |
| Property, Plant & Equipment | ₩57.57 Billion | 54.1% |
| Intangible Assets | ₩344.20 Million | 0.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Genolution Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Genolution Inc. market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genolution Inc.'s current assets represent 35.0% of total assets in 2024, a decrease from 80.0% in 2016.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 54.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 11.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 54.1% of total assets.
Genolution Inc. Competitors by Total Assets
Key competitors of Genolution Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $1.30 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Genolution Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.48 | 3.41 | 4.01 |
| Quick Ratio | 5.06 | 3.23 | 3.81 |
| Cash Ratio | 0.00 | 0.47 | 0.00 |
| Working Capital | ₩28.75 Billion | ₩27.76 Billion | ₩47.61 Billion |
Genolution Inc. - Advanced Valuation Insights
This section examines the relationship between Genolution Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.41 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -6.2% |
| Total Assets | ₩106.45 Billion |
| Market Capitalization | $22.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genolution Inc.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genolution Inc.'s assets decreased by 6.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genolution Inc. (2016–2024)
The table below shows the annual total assets of Genolution Inc. from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩106.45 Billion ≈ $72.14 Million |
-6.16% |
| 2023-12-31 | ₩113.44 Billion ≈ $76.88 Million |
-0.89% |
| 2022-12-31 | ₩114.45 Billion ≈ $77.56 Million |
+20.55% |
| 2021-12-31 | ₩94.94 Billion ≈ $64.34 Million |
+13.33% |
| 2020-12-31 | ₩83.77 Billion ≈ $56.77 Million |
+523.86% |
| 2019-12-31 | ₩13.43 Billion ≈ $9.10 Million |
+21.01% |
| 2018-12-31 | ₩11.10 Billion ≈ $7.52 Million |
+135.83% |
| 2017-12-31 | ₩4.71 Billion ≈ $3.19 Million |
+17.78% |
| 2016-12-31 | ₩3.99 Billion ≈ $2.71 Million |
-- |
About Genolution Inc.
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/… Read more